[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367707-105":59,"doc-detail-367707-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","radionuclides-landscape-in-prostate-cancer-theranostics-review","Radionuclides Landscape in Prostate Cancer Theranostics - Review","","Prostate cancer is a highly prevalent malignancy affecting hundreds of thousands of men in Europe. Radiotheranostics advances prostate cancer management by using radionuclides for both diagnostics and therapy, with PSMA serving as the key molecular target. Regulatory approvals include PSMA-targeted radiodiagnostic agents such as [18F]DCFPyL, [18F]rhPSMA-7.3 and [68Ga]Ga-PSMA-11, alongside the therapeutic agent [177Lu]Lu-PSMA-617 and the later approval of PLUVICTO® for metastatic castration-resistant disease. The review summarizes additional radionuclides used or under clinical investigation and compares 177Lu, 225Ac and 223Ra, outlining mechanisms, clinical applications, and major challenges.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/radionuclides-landscape-in-prostate-cancer-theranostics-review/367707/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/radionuclides-landscape-in-prostate-cancer-theranostics-review/367707.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"Which therapeutic radionuclide is discussed as a major treatment option?","Question",{"text":112,"@type":113},"The review emphasizes the therapeutic use of [177Lu]Lu-PSMA-617 (PLUVICTO®), including its approval for metastatic castration-resistant prostate cancer after prior treatments.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},367707,1790206860,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nRadionuclides Landscape in Prostate Cancer Theranostics  \nMonica Neagu 1,2,3, *,†, Carolina Constantin 1,2,†, Mihail Eugen Hinescu 1,4, Petrisor Gabriel Bleotu 5, Mara-Georgiana Popovici 5,6, Maria-Iulia Zai 5 and Klaus Michael Spohr 5,7  \nAcademic Editor: Shafiq Khan  \nReceived: 17 June 2025  \nRevised: 7 July 2025  \nAccepted: 11 July 2025  \nPublished: 14 July 2025  \nCitation: Neagu, M.; Constantin, C.; Hinescu, M.E.; Bleotu, P.G.; Popovici, M.-G.; Zai, M.-I.; Spohr, K.M. Radionuclides Landscape in Prostate Cancer Theranostics. Int. J. Mol. Sci. 2025, 26, 6751. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms26146751](10.3390/ijms26146751)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 “Victor Babes” National Institute, 99-01 Splaiul Independentei, 050096 Bucharest, Romania; [caroconstantin@gmail.com](caroconstantin@gmail.com) (C.C.); [mhinescu@yahoo.com](mhinescu@yahoo.com) (M.E.H.)  \n2 Colentina Clinical Hospital, 19-21 Soseaua Stefan cel Mare, 020125 Bucharest, Romania  \n3 Faculty of Biology, University of Bucharest, 91-95 Splaiul Independentei, 050107 Bucharest, Romania  \n4 Department of Cellular and Molecular Biology and Histology,“Carol Davila” University of Medicine and Pharmacy, 8 Bulevardul Eroii Sanitari, 050474 Bucharest, Romania  \n5 Extreme Light Infrastructure-Nuclear Physics (ELI-NP),“Horia Hulubei” National Institute for Physics and Nuclear Engineering (IFIN-HH), 30 Reactorului Street, 077125 Magurele, Romania;  \n[gabriel.bleotu@eli-np.ro](gabriel.bleotu@eli-np.ro) (P.G.B.); [mara.popovici@eli-np.ro](mara.popovici@eli-np.ro) (M.-G.P.); [iulia.zai@eli-np.ro](iulia.zai@eli-np.ro) (M.-I.Z.);  \n[klaus.spohr@eli-np.ro](klaus.spohr@eli-np.ro) (K.M.S.)  \n6 Doctoral School of Applied Science, National University of Science and Technology Politehnica of Bucharest, Splaiul Independentei 313, 060042 Bucharest, Romania  \n7 School of Computing, Engineering and Physical Sciences, University of the West of Scotland, High Street, Paisley PA1 2BE, UK  \n* [Correspondence: neagu.monica@gmail.com](Correspondence: neagu.monica@gmail.com)  \n† These authors contributed equally to this work.  \nAbstract  \nProstate cancer, a malignancy of significant prevalence, affects approximately half a million men in Europe, with one in twelve males receiving a diagnosis before reaching the age of 75 . Radiotheranostics represents a paradigm shift in prostate cancer treatment, leveraging radionuclides for diagnostic and therapeutic applications, with PSMA emerging as the primary molecular target. Regulatory bodies have approved various PSMA-targeted radiodiagnostic agents, such as [18F]DCFPyL (PYLARIFY®, Lantheus Holdings),[18F]rhPSMA-7 .3 (POSLUMA® , Blue Earth Diagnostics), and [68Ga]Ga-PSMA- 11 (LOCAMETZ® , Novartis/ILLUCCIX®, Telix Pharmaceuticals), as well as therapeutic agents like [177Lu]Lu-PSMA-617 (PLUVICTO® , 15 Novartis) . The approval of PLUVICTO® in March 2022 for patients with metastatic castration-resistant prostate cancer who have undergone prior treatments, including androgen receptor pathway-targeting agents and taxane-based chemotherapy, represents a significant advancement. Other radionuclides like 161Tb, 149Tb, 225Ac, 227Th, 223Ra, 211At, 213 Bi, 212Pb, 89Zr, and 125I are presented, emphasizing their clinical implementation or the stage of clinical trial they are in in the flow to biomedical implementation. Three clinically wise used radionuclides 177Lu, 225Ac, 223Ra are shown along with their characteristics. This review aims to elucidate the molecular mechanisms underpinning PSMA, explore the clinical applications of PSMA-targeted radiotheranostics, and critically examine the diverse challenges these thera","cbCailwFX6iwPSvl","https://ap.wps.com/l/cbCailwFX6iwPSvl","pdf",639923,23,"English","# 1. Introduction\n## Prostate cancer epidemiology and screening\n## Localized to castration-resistant progression\n## Clinical management and therapy resistance\n# Abstract\n## Radiotheranostics and PSMA targeting\n## Approved diagnostic and therapeutic radionuclides\n## Additional radionuclides in clinical development\n## Review aims and scope","[{\"question\":\"Which therapeutic radionuclide is discussed as a major treatment option?\",\"answer\":\"The review emphasizes the therapeutic use of [177Lu]Lu-PSMA-617 (PLUVICTO®), including its approval for metastatic castration-resistant prostate cancer after prior treatments.\"}]","Radionuclides Landscape in Prostate Cancer Theranostics - Review | PDF",1790172162,58,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40a5a225a297ff1edcb3426730b13d64.webp",983,1390,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1625088389d99c74664570e3caae6c5.webp",982,1388,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac35da3dfa654ca387204f1214d788f7.webp",981,1387,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce6e69ae5a4caa13c2efa3ce32fea193.webp",980,1385]